Your session is about to expire
← Back to Search
Study Summary
This trial aims to determine if AMDX-2011P can be used to detect amyloid deposits in the retina of individuals with Primary Open Angle Glaucoma (POAG).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants currently being actively recruited for this research study?
"Indeed, the information provided on clinicaltrials.gov indicates that this ongoing clinical trial is actively seeking patients. The trial was initially posted for recruitment purposes on December 7th, 2023 and has been recently updated as of January 23rd, 2024. For this study, a total of 50 participants will be admitted at a single designated site."
What is the current number of individuals being recruited for participation in this clinical investigation?
"Indeed, the data available on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible participants. The initial posting of the trial occurred on December 7th, 2023, and it was last updated on January 23rd, 2024. For this study, they aim to recruit a total of 50 individuals from one designated site."
What are the potential risks and adverse effects associated with a dosage of 50 mg of AMDX-2011P for patients?
"Based on our evaluation, the safety of AMDX-2011P 50 mg is estimated to be at level 2. This assessment is derived from it being a Phase 2 trial where some evidence suggests its safety, but there is currently no data supporting its efficacy."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger